Jade Biosciences (JBIO) Accounts Payables (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Accounts Payables came in at $4.0 million in Q1 2026, up 5666.67% YoY from $69000.0 in Q1 2025, and up 84.98% on a QoQ basis from $2.2 million in Q4 2025.
Jade Biosciences (JBIO) Accounts Payables (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Accounts Payables data on file, last reported at $4.0 million in Q1 2026.
- Quarterly Accounts Payables rose 5666.67% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 5666.67% YoY) and the FY2025 annual result came in at $2.2 million, up 66.74% from the prior year.
- Accounts Payables advanced to $4.0 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $7.6 million in Q2 2025 to a low of $69000.0 in Q1 2025.
- A 5-year average of $3.1 million and a median of $2.9 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2025 — Accounts Payables slumped 97.92% — and 2026, when it surged 5666.67%.
- Tracing JBIO's Accounts Payables over 5 years: stood at $2.6 million in 2022, then dropped by 6.95% to $2.4 million in 2023, then plunged by 46.16% to $1.3 million in 2024, then jumped by 66.74% to $2.2 million in 2025, then soared by 84.98% to $4.0 million in 2026.
- The last three Accounts Payables figures came in at $4.0 million (Q1 2026), $2.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | 6.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.58 Mn |
| Mar 31, 2026 | 3.98 Mn |
| Dec 31, 2025 | 2.15 Mn |
| Sep 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 7.59 Mn |
| Mar 31, 2025 | 69,000.00 |
| Dec 31, 2024 | 1.29 Mn |
| Sep 30, 2024 | 908,000.00 |
| Jun 30, 2024 | 4.18 Mn |
| Mar 31, 2024 | 3.31 Mn |
| Dec 31, 2023 | 2.40 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | 5.53 Mn |
| Mar 31, 2023 | 4.73 Mn |
| Dec 31, 2022 | 2.58 Mn |
| Sep 30, 2022 | 4.54 Mn |
| Jun 30, 2022 | 2.07 Mn |
| Mar 31, 2022 | 2.86 Mn |
| Dec 31, 2021 | 1.21 Mn |
| Sep 30, 2021 | 2.56 Mn |